|
GB8531071D0
(en)
*
|
1985-12-17 |
1986-01-29 |
Boots Co Plc |
Therapeutic compound
|
|
CA2138998A1
(en)
*
|
1992-06-23 |
1994-01-06 |
James W. Young |
Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine
|
|
AU721924B2
(en)
*
|
1992-06-23 |
2000-07-20 |
Sepracor, Inc. |
Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
|
|
GB9311920D0
(en)
|
1993-06-09 |
1993-07-28 |
Pfizer Ltd |
Therapeutic agents
|
|
US5459164A
(en)
*
|
1994-02-03 |
1995-10-17 |
Boots Pharmaceuticals, Inc. |
Medical treatment
|
|
DE19518988A1
(en)
*
|
1995-05-29 |
1996-12-05 |
Basf Ag |
Use of aryl substituted cyclobutylalkylamines to treat obesity
|
|
GB9619757D0
(en)
|
1996-09-21 |
1996-11-06 |
Knoll Ag |
Chemical process
|
|
GB9619962D0
(en)
*
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
|
GB9619961D0
(en)
|
1996-09-25 |
1996-11-13 |
Knoll Ag |
Medical treatment
|
|
GB9727131D0
(en)
|
1997-12-24 |
1998-02-25 |
Knoll Ag |
Therapeutic agents
|
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
|
US6476078B2
(en)
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
|
US6046242A
(en)
*
|
1998-11-27 |
2000-04-04 |
Basf Aktiengesellschaft |
Use of aryl-substituted cyclobutylalkylamines for treating urinary incontinence
|
|
US6696495B2
(en)
*
|
1998-12-02 |
2004-02-24 |
Snowden Pharmaceuticals, Llc |
Treatment of disorders secondary to organic impairments
|
|
US6323242B1
(en)
|
1998-12-02 |
2001-11-27 |
Peter Sterling Mueller |
Treatment of disorders secondary to organic impairments
|
|
CN1188120C
(en)
*
|
1999-03-17 |
2005-02-09 |
艾博特股份有限两合公司 |
Methods of Treating Eating Disorders
|
|
BG65170B1
(en)
*
|
1999-03-17 |
2007-05-31 |
Knoll Gmbh |
Use of n-substituted derivatives of 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl amine for the production of a medicine for treating eating disorders
|
|
US6803387B1
(en)
*
|
1999-03-19 |
2004-10-12 |
Abbott Gmbh & Co. Kg |
Treatment of neuropathic pain or fibromyalgia
|
|
WO2000056306A1
(en)
*
|
1999-03-19 |
2000-09-28 |
Knoll Gmbh |
Treatment of osteoarthritis
|
|
WO2000056321A1
(en)
|
1999-03-19 |
2000-09-28 |
Knoll Pharmaceutical Company |
Treatment of hyperactivity disorders
|
|
CA2368416A1
(en)
*
|
1999-03-19 |
2000-09-28 |
Knoll Gmbh |
Treatment of gallstones
|
|
JP2002539250A
(en)
|
1999-03-19 |
2002-11-19 |
クノール・ゲー・エム・ベー・ハー |
Treatment of pulmonary hypertension
|
|
HUP0200501A3
(en)
*
|
1999-03-19 |
2004-03-29 |
Abbott Gmbh & Co Kg |
Use of n,n-dimethyl-1-[1-(4chlorophenyl)cyclobutyl]-3-methylbutylamine for treating sleep apnoea
|
|
US6433020B1
(en)
|
1999-03-19 |
2002-08-13 |
Knoll Pharmaceutical Company |
Treatment of cardiovascular disease
|
|
JP2002539251A
(en)
*
|
1999-03-19 |
2002-11-19 |
クノール・ゲー・エム・ベー・ハー |
How to control weight gain associated with therapeutics
|
|
AU3895300A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Treatment of chronic fatigue syndrome
|
|
EP1162966A4
(en)
*
|
1999-03-19 |
2002-06-12 |
Knoll Gmbh |
Weight loss after pregnancy
|
|
AU3895400A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Control of metabolism
|
|
AU3760600A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Treatment of orthostatic hypotension
|
|
US6552087B1
(en)
|
1999-03-19 |
2003-04-22 |
Abbott Gmbh & Co. Kg |
Therapeutic agent comprising (+)-sibutramine
|
|
AU3894600A
(en)
|
1999-03-19 |
2000-10-09 |
Knoll Pharmaceutical Company |
Method of treating sexual dysfunction
|
|
US6245782B1
(en)
|
1999-05-17 |
2001-06-12 |
Heartdrug Research L.L.C. |
Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
|
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
|
GB9926251D0
(en)
*
|
1999-11-06 |
2000-01-12 |
Knoll Ag |
Pharmaceutical formulation
|
|
GB0004003D0
(en)
*
|
2000-02-22 |
2000-04-12 |
Knoll Ag |
Therapeutic agents
|
|
WO2002019998A2
(en)
*
|
2000-09-08 |
2002-03-14 |
Eli Lilly And Company |
A method of treating weight gain associated with atypical antipsychotic use
|
|
US20020091114A1
(en)
|
2000-10-04 |
2002-07-11 |
Odile Piot-Grosjean |
Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity
|
|
FR2814678B1
(en)
†
|
2000-10-04 |
2002-12-20 |
Aventis Pharma Sa |
COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY
|
|
US6610887B2
(en)
|
2001-04-13 |
2003-08-26 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
|
US20030139386A1
(en)
*
|
2001-12-21 |
2003-07-24 |
Sophie Cote |
Pharmaceutical compositions based on azetidine derivatives
|
|
NZ534757A
(en)
*
|
2002-03-12 |
2006-07-28 |
Merck & Co Inc |
Substituted amides
|
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
|
US20040122033A1
(en)
*
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
US20050131074A1
(en)
*
|
2003-08-04 |
2005-06-16 |
Beckman Kristen M. |
Methods for treating metabolic syndrome
|
|
ATE547404T1
(en)
|
2003-09-22 |
2012-03-15 |
Msd Kk |
PIPERIDINE DERIVATIVES
|
|
EP1734963A4
(en)
|
2004-04-02 |
2008-06-18 |
Merck & Co Inc |
METHOD FOR TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS
|
|
CN101098850B
(en)
|
2005-01-06 |
2010-09-15 |
Cj第一制糖株式会社 |
Inorganic acid salt of sibutramine
|
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
|
NZ562766A
(en)
|
2005-05-30 |
2011-03-31 |
Banyu Pharma Co Ltd |
Piperidine derivatives as histamine-H3 receptor antagonists
|
|
US20100216758A1
(en)
|
2005-08-10 |
2010-08-26 |
Makoto Ando |
Pyridone Compounds
|
|
AU2006282260A1
(en)
|
2005-08-24 |
2007-03-01 |
Msd K.K. |
Phenylpyridone derivative
|
|
EP1939194A4
(en)
|
2005-09-07 |
2010-12-08 |
Banyu Pharma Co Ltd |
AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
|
|
WO2007034910A1
(en)
*
|
2005-09-22 |
2007-03-29 |
Eisai R & D Management Co., Ltd. |
Medicinal composition for treating bulimia and depression accompanying bulimia
|
|
CN101277960A
(en)
|
2005-09-29 |
2008-10-01 |
默克公司 |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
|
US8911751B2
(en)
*
|
2005-10-11 |
2014-12-16 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions for nasal delivery
|
|
WO2007048027A2
(en)
|
2005-10-21 |
2007-04-26 |
Novartis Ag |
Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
|
|
CA2627139A1
(en)
|
2005-10-27 |
2007-05-03 |
Banyu Pharmaceutical Co., Ltd. |
Novel benzoxathiin derivative
|
|
WO2007055418A1
(en)
|
2005-11-10 |
2007-05-18 |
Banyu Pharmaceutical Co., Ltd. |
Aza-substituted spiro derivative
|
|
US8748419B2
(en)
|
2006-06-16 |
2014-06-10 |
Theracos, Inc. |
Treating obesity with muscarinic receptor M1 antagonists
|
|
RU2477634C2
(en)
*
|
2006-06-16 |
2013-03-20 |
Теракос, Инк. |
Treating psychological conditions with using m1-muscarinic antagonists
|
|
BRPI0716134A2
(en)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
combination treatment for diabetes mellitus
|
|
MX2009002781A
(en)
*
|
2006-09-15 |
2009-03-30 |
Reviva Pharmaceuticals Inc |
Synthesis, methods of using, and compositions of cycloalkylmethylamines.
|
|
US8604244B2
(en)
|
2010-07-02 |
2013-12-10 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
|
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
|
AU2007301126A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
|
MX2009010925A
(en)
*
|
2007-04-09 |
2009-11-02 |
Scidose Llc |
Combinations of statins and anti-obesity agent.
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
WO2008151257A2
(en)
|
2007-06-04 |
2008-12-11 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
WO2008149345A2
(en)
|
2007-06-04 |
2008-12-11 |
Ben-Gurion University Of The Negev Research And Development Authority |
Tri-aryl compounds and compositions comprising the same
|
|
JPWO2009110510A1
(en)
|
2008-03-06 |
2011-07-14 |
Ｍｓｄ株式会社 |
Alkylaminopyridine derivatives
|
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
CA2727914A1
(en)
|
2008-06-19 |
2009-12-23 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diaryl ketoxime derivative technical field
|
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
EP2319841A1
(en)
|
2008-07-30 |
2011-05-11 |
Msd K.K. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
US20100311710A1
(en)
*
|
2008-12-06 |
2010-12-09 |
Auspex Pharmaceuticals, Inc. |
Cyclobutanemethanamine inhibitors of monoamine reuptake
|
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
|
WO2010075068A1
(en)
|
2008-12-16 |
2010-07-01 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
BR112013021236B1
(en)
|
2011-02-25 |
2021-05-25 |
Merck Sharp & Dohme Corp |
benzimidazole derivative compound, and, composition
|
|
US9527875B2
(en)
|
2012-08-02 |
2016-12-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
MX2015010935A
(en)
|
2013-02-22 |
2015-10-29 |
Merck Sharp & Dohme |
Antidiabetic bicyclic compounds.
|
|
US9650375B2
(en)
|
2013-03-14 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Indole derivatives useful as anti-diabetic agents
|
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
AU2014274812B2
(en)
|
2013-06-05 |
2018-09-27 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase C, method of making and using same
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
CN106061940A
(en)
|
2013-11-05 |
2016-10-26 |
本古里安大学内盖夫研究发展局 |
Compounds for the treatment of diabetes and its associated diseases
|
|
DK3186242T3
(en)
|
2014-08-29 |
2021-12-20 |
Tes Pharma S R L |
ALFA-AMINO-BETA-CARBOXYMUCONSIDE-SEMIALDEHYDE-DECARBOXYLASE INHIBITORS
|
|
AR109950A1
(en)
|
2016-10-14 |
2019-02-06 |
Tes Pharma S R L |
A-AMINO-b-CARBOXIMUCONIC SEMIAL DEHYDE DECARBOXYLASE ACID INHIBITORS
|
|
EP3551176A4
(en)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC HETEROCYCLIC COMPOUNDS
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
BR112021009589A2
(en)
|
2018-11-20 |
2021-08-17 |
Tes Pharma S.R.L. |
alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase inhibitors
|